FDA approves second Ebola treatment

The Ebola virus can cause potentially deadly human diseases.
it is transmitted through direct contact with the blood, body fluids and tissues of an infected person or wild animal, and individuals who provide care to people infected with Ebola virus, including health care workers who do not use proper infection control precautions, are at the highest risk of infection.
Ebanga (ansuvimab-zykl) is a monoclonal antibody isolated from survivors of the 1995 Ebola outbreak in the Democratic Republic of the Congo.
Nancy Sullivan of the National Institute of Allergy and Infectious Diseases (NIAID) Virus Research Center, together with scientists from Humabs BioMed, a subsidiary of Vir Biotechnology, found that survivors retained antibodies against Ebola 11 years after infection.
team isolated the antibodies and chose ansuvimab as the most promising antibody in clinical trials. The results of the
PALM clinical trial were published in the New England Journal of Medicine (photo source, New England Journal of Medicine) During the 2018-2019 Ebola outbreak in the Democratic Republic of the Congo, the safety and effectiveness of Ebanga was evaluated in a multi-center, open-label, randomized controlled trial called PALM.
174 subjects (120 adults and 54 children) who were diagnosed with Ebola virus infection received a single intravenous injection from Ebanga, and 168 subjects (135 adults and 33 children) received trial-controlled treatment.
efficacy of the disease was the mortality rate after 28 days of treatment.
of the 174 patients treated with Ebanga, 35.1 per cent died after 28 days, while 49.4 per cent of the 168 patients treated with control died after 28 days.
: s1. Ridgeback Biotherapeutics LP Announces the Approval of EbangaTM for Ebola. Retrieved December 22, 2020, from [2] FDA Approves Treatment for Ebola Virus. Retrieved December 22, 2020, from。